The HORIZON Recurrent Fracture Trial tested whether yearly intravenous zoledronic acid reduces new clinical fractures and mortality after repair of a low-trauma hip fracture. Double-blind RCT of 2127 patients (mean age 74.5) given 5 mg zoledronic acid (1065) or placebo (1062) yearly from within 90 days of repair. Median follow-up 1.9 years. Primary end point: new clinical fracture.
The HORIZON Recurrent Fracture Trial tested whether yearly intravenous zoledronic acid reduces new clinical fractures and mortality after repair of a low-trauma hip fracture. Double-blind RCT of 2127 patients (mean age 74.5) given 5 mg zoledronic acid (1065) or placebo (1062) yearly from within 90 days of repair. Median follow-up 1.9 years. Primary end point: new clinical fracture.